Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection
NCT ID: NCT00400322
Last Updated: 2021-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
42 participants
INTERVENTIONAL
2006-08-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
NCT00294515
A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS
NCT00002222
Cytomegalovirus Reactivation in Cancer Patients Receiving Chemotherapy
NCT00366717
In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir
NCT01037712
An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients
NCT02062294
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Valganciclovir
Valganciclovir (Valcyte)
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Valganciclovir (Valcyte)
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cytomegalovirus detected in tumor
* At least 90% resection of tumor
Exclusion Criteria
* Pregnancy
* Neutropenia
* Thrombocytopenia
* Patient not tolerating the drug
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karolinska University Hospital
OTHER
Karolinska Institutet
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cecilia Soderberg-Naucler
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Inti Peredo, MD
Role: PRINCIPAL_INVESTIGATOR
Karolinska University Hospital
Cecilia Soderberg-Naucler, MD, PhD
Role: STUDY_CHAIR
Karolinska Institutet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of neurosurgery, Karolinska University Hospital
Solna, Stockholm County, Sweden
Department of Oncology, Norrland University Hospital
Umeå, , Sweden
Department of Oncology, Akademiska Hospital
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006-002022-29
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
MV20145
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.